VYNE Therapeutics (NASDAQ:VYNE) Coverage Initiated by Analysts at BTIG Research

BTIG Research began coverage on shares of VYNE Therapeutics (NASDAQ:VYNE) in a research note published on Monday morning, MarketBeat reports. The firm issued a buy rating and a $8.00 target price on the stock.

Separately, HC Wainwright reissued a “buy” rating and issued a $5.75 target price on shares of VYNE Therapeutics in a report on Friday, November 8th.

VYNE Therapeutics Trading Up 0.7 %

Shares of VYNE Therapeutics stock opened at $2.72 on Monday. The firm has a market cap of $40.12 million, a PE ratio of -3.16 and a beta of 1.32. The stock has a 50 day moving average of $2.29 and a 200 day moving average of $2.19. VYNE Therapeutics has a 12 month low of $1.57 and a 12 month high of $4.24.

Institutional Investors Weigh In On VYNE Therapeutics

An institutional investor recently bought a new position in VYNE Therapeutics stock. Lynx1 Capital Management LP purchased a new position in VYNE Therapeutics Inc. (NASDAQ:VYNE) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 16,194 shares of the company’s stock, valued at approximately $32,000. VYNE Therapeutics comprises approximately 0.0% of Lynx1 Capital Management LP’s holdings, making the stock its 17th biggest position. Lynx1 Capital Management LP owned about 0.11% of VYNE Therapeutics as of its most recent SEC filing. Institutional investors own 83.78% of the company’s stock.

About VYNE Therapeutics

VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.